Chemistry:Ziftomenib
From HandWiki
Ziftomenib is an experimental drug for the treatment of cancer. It is being studied for use in patients with relapsed or refractory acute myeloid leukaemia.[1][2]
Ziftomenib blocks the interaction between two proteins, menin (MEN1) and KMT2A (also known as mixed lineage leukemia protein, MLL).[3][4] This results in an inhibition of the proliferation of leukemic cells.
Ziftomenib has been granted breakthrough therapy designation by the Food and Drug Administration.[5]
References
- ↑ "Ziftomenib in relapsed or refractory acute myeloid leukaemia (KOMET-001): a multicentre, open-label, multi-cohort, phase 1 trial". The Lancet. Oncology 25 (10): 1310–1324. October 2024. doi:10.1016/S1470-2045(24)00386-3. PMID 39362248.
- ↑ "Ziftomenib Meets CR/CRh End Point in R/R NPM1+ AML". February 6, 2025.
- ↑ "Ziftomenib". NCI Cancer Dictionary. National Cancer Institute. https://www.cancer.gov/publications/dictionaries/cancer-drug/def/ziftomenib.
- ↑ "Menin inhibitor ziftomenib (KO-539) synergizes with drugs targeting chromatin regulation or apoptosis and sensitizes acute myeloid leukemia with MLL rearrangement or NPM1 mutation to venetoclax". Haematologica 108 (10): 2837–2843. October 2023. doi:10.3324/haematol.2022.282160. PMID 37102614.
- ↑ "FDA Grants Breakthrough Therapy Designation to Ziftomenib in NPM1-Mutant AML". April 22, 2024. https://www.onclive.com/view/fda-grants-breakthrough-therapy-designation-to-ziftomenib-in-npm1-mutant-aml.
 |  |
